Joachim Eeckhout, Author at Labiotech.eu

About

Founder & Managing Director at Labiotech.eu. While I was studying biotechnology in Paris, I got frustrated by the lack of digital media available for the industry and decided to fix it! I launched Labiotech.eu in 2014 and grew it to the largest community for biotech professionals in Europe! Other than biotech news, I’m also a heavy reader of Sci-Fi and Fantasy.

Articles by Joachim Eeckhout

LaBiotech Zurich Life Science Day2 cover

News and Trends 9 Mar 2015

An Inside Look: Zurich Life Science Day 2015

Over 600 people from all stretches of the globe gathered on February 12 for the Zurich Life Science Day at the University of Zurich. My first impression walking there was that the campus (both the Irchel campus it was held at and main campus I mistakenly went to first) were beautiful. I had low expectations […]

March 9, 2015 - 7 minutesmins - By Joachim Eeckhout

News and Trends 6 Mar 2015

Global Bioenergies Produces its First “Second Generation” Isobutene

We already presented Global Bioenergies in our article “Is France leading the European Synthetic Biology-based Biofuel field?”, but as a reminder the company is developing a process to convert renewable resources into hydrocarbons (more specifically isobutene, a building blocks that can be converted into fuels, plastics, organic glass and elastomers) through fermentation. Global Bioenergies annouced having […]

March 6, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 3 Mar 2015

Calixar Raises €1 Million to License-out its Isolation Technologies

CALIXAR, develops new approaches to isolate in solution – with the highest purity levels – full-length membrane antigens and proteins, whilst keeping their structural and functional integrity. The company announced the completion of its second round of financing with its historical investors, Bpifrance (French public investment bank) and the Banque Populaire. The aim of this […]

March 3, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 2 Mar 2015

Monsanto Reaffirms its Commitment in Europe

While the “Salon International de l’Agriculture 2015” has just closed its doors in Paris, Monsanto, a global provider of leading technology solutions and products that improves farm productivity, reaffirms its commitment to the European market of seeds. Monsanto’s strategy includes investments of €500 million over ten years to develop the company’s production capacity in Europe […]

March 2, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 27 Feb 2015

Sanofi: Get Ready for the Launch of the First Inhaled Insulin in the U.S.

Sanofi, the global healthcare leader has core strengths in the field of healthcare due to its seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. This article will focus on Sanofi Diabetes. In August 2014, our previous article “Sanofi buys Mannkind’s inhaled insulin for €824.5m” […]

February 27, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 25 Feb 2015

Cellectis is preparing its IPO in the U.S

Cellectis is a company focused on developing immunotherapies based on gene edited engineered CAR-T cells. The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. With 15 years of expertise, Cellectis is already listed on the NYSE Alternext market (ticker: ALCLS) and now preparing its IPO to be listed on the […]

February 25, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 22 Feb 2015

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine

THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its therapeutic vaccine candidate for the treatment of Adult T-cell Leukemia/Lymphoma (ATL/L). ATL/L is a rare malignancy of a certain type of white cells, T-Lymphocytes, caused by the Human T-Cell Lymphotropic Virus type […]

February 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 20 Feb 2015

2014, an amazing year for CARMAT

CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people with irreversible terminal heart failure. This concerns the sickest of the 20 million patients affected by this progressive disease in Europe and the United States. 2014 was an eventful year for the company, the publication of 2014 annual […]

February 20, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 11 Feb 2015

Hello Tomorrow Challenge, the startup competition with €100k to win!

The second edition of the Hello Tomorrow Challenge has been launched in December 2014. This is a great opportunity for startups, students and researchers to transform their innovative technologies into impactful products. The Challenge is open to innovative startups and research projects which: Are based on innovative technology Are under 2 years old (if incorporated) […]

February 11, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 11 Feb 2015

AB Science: One step further towards a cure to Alzheimer’s disease

AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), today announced the successful completion of a futility analysis related to the masitinib phase 3 trial for the treatment of mild to moderate Alzheimer’s disease. Today, between 5 and 10 million people suffer from Alzheimer’s disease in the USA […]

February 11, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 7 Feb 2015

Fermentalg launch an Omega-3 enriched oil produced by microalgae

Six years after the creation of the company, Fermentalg, an industrial biotechnology company that specializes in the production of oils and proteins derived from microalgae, has received the European Novel Food authorization for its first product: DHA-enriched oil (Omega-3) for the vast human nutrition market. Obtaining this authorization means Fermentalg has achieved one of the priority […]

February 7, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 8 Jan 2015

Nanobiotix on its way to change the paradigm in cancer therapy

Nanobiotix is an oncology focused nanomedicine company developing an innovative nanoparticle technology. Their NanoXray technology comprises three products having the potential to cause a paradigm shift in cancer therapy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. The following video is showing how this disruptive technology is acting […]

January 8, 2015 - 4 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us